XTANT MEDICAL (Germany) Performance
| XMS Stock | EUR 0.34 0.01 3.03% |
The firm owns a Beta (Systematic Risk) of 0.22, which attests to not very significant fluctuations relative to the market. As returns on the market increase, XTANT MEDICAL's returns are expected to increase less than the market. However, during the bear market, the loss of holding XTANT MEDICAL is expected to be smaller as well. At this point, XTANT MEDICAL HLDGS has a negative expected return of -0.65%. Please make sure to check out XTANT MEDICAL's treynor ratio, kurtosis, and the relationship between the jensen alpha and potential upside , to decide if XTANT MEDICAL HLDGS performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days XTANT MEDICAL HLDGS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
XTANT |
XTANT MEDICAL Relative Risk vs. Return Landscape
If you would invest 56.00 in XTANT MEDICAL HLDGS on September 23, 2024 and sell it today you would lose (22.00) from holding XTANT MEDICAL HLDGS or give up 39.29% of portfolio value over 90 days. XTANT MEDICAL HLDGS is currently producing negative expected returns and takes up 4.598% volatility of returns over 90 trading days. Put another way, 40% of traded stocks are less volatile than XTANT, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
XTANT MEDICAL Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for XTANT MEDICAL's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as XTANT MEDICAL HLDGS, and traders can use it to determine the average amount a XTANT MEDICAL's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1411
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XMS |
Estimated Market Risk
| 4.6 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.65 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average XTANT MEDICAL is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of XTANT MEDICAL by adding XTANT MEDICAL to a well-diversified portfolio.
XTANT MEDICAL Fundamentals Growth
XTANT Stock prices reflect investors' perceptions of the future prospects and financial health of XTANT MEDICAL, and XTANT MEDICAL fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XTANT Stock performance.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0619 | |||
| Profit Margin | (0.15) % | |||
| Operating Margin | (0.1) % | |||
| Shares Outstanding | 108.66 M | |||
| Revenue | 56.67 M | |||
| EBITDA | (4.28 M) | |||
| Cash And Equivalents | 20.31 M | |||
| Cash Per Share | 0.23 X | |||
| Total Debt | 17.43 M | |||
| Debt To Equity | 0.51 % | |||
| Book Value Per Share | 0.32 X | |||
| Cash Flow From Operations | 1.79 M | |||
| Earnings Per Share | (0.08) X | |||
About XTANT MEDICAL Performance
By analyzing XTANT MEDICAL's fundamental ratios, stakeholders can gain valuable insights into XTANT MEDICAL's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if XTANT MEDICAL has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if XTANT MEDICAL has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana. XTANT MEDICAL operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 110 people.Things to note about XTANT MEDICAL HLDGS performance evaluation
Checking the ongoing alerts about XTANT MEDICAL for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XTANT MEDICAL HLDGS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XTANT MEDICAL HLDGS generated a negative expected return over the last 90 days | |
| XTANT MEDICAL HLDGS has some characteristics of a very speculative penny stock | |
| XTANT MEDICAL HLDGS has high historical volatility and very poor performance | |
| XTANT MEDICAL HLDGS has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 56.67 M. Net Loss for the year was (2.83 M) with profit before overhead, payroll, taxes, and interest of 32.49 M. | |
| Over 75.0% of the company outstanding shares are owned by institutional investors |
- Analyzing XTANT MEDICAL's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XTANT MEDICAL's stock is overvalued or undervalued compared to its peers.
- Examining XTANT MEDICAL's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XTANT MEDICAL's management team can have a significant impact on its success or failure. Reviewing the track record and experience of XTANT MEDICAL's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XTANT MEDICAL's stock. These opinions can provide insight into XTANT MEDICAL's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for XTANT Stock analysis
When running XTANT MEDICAL's price analysis, check to measure XTANT MEDICAL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTANT MEDICAL is operating at the current time. Most of XTANT MEDICAL's value examination focuses on studying past and present price action to predict the probability of XTANT MEDICAL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTANT MEDICAL's price. Additionally, you may evaluate how the addition of XTANT MEDICAL to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |